Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin
β Scribed by Xiaodong Zhu; Jiin Leaw; Weilie Gu; Yiying Qian; Hongyu Du; Biyun Wang; Xiaonan Hong; Jiliang Yin
- Publisher
- Springer-Verlag
- Year
- 2008
- Tongue
- English
- Weight
- 291 KB
- Volume
- 134
- Category
- Article
- ISSN
- 1432-1335
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer
## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d